Director/PDMR Shareholding

RNS Number : 0106T

e-Therapeutics plc

15 July 2020

 

E-THERAPEUTICS PLC

("e-therapeutics" or the "Company")

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS

DISCHARGING MANAGERIAL RESPONSIBILITIES AND ISSUE OF EQUITY

Oxford, UK, 15 July 2020   - e-therapeutics plc (AIM: ETX), the drug discovery company, announces that on 14 July 2020 Professor Trevor Jones (Non-Executive Director) subscribed for a total of 32,185 new ordinary shares of 0.1p each in the Company (the "New Ordinary Shares") at a price of 17.09 pence per share. The subscription monies paid for the New Ordinary Shares represent 50% of Professor Jones' Non-Executive Director fees net of tax paid during the period from 1 January 2020 to 30 June 2020 in accordance with the agreement entered into with Professor Jones, previously announced on 5 October 2016,  by which Professor Jones agreed, with effect from 1 October 2016, to invest 50% of his annual Non-Executive Director fees net of tax in new e-therapeutics' ordinary shares. Such new shares are issued to Professor Jones on the first business day after 31 December and 30 June in each year. The subscription price to be paid is the average of the closing mid-market price for the five business days prior to the date of issue.

Following Admission, Professor Jones will be interested in a total of 998,538 ordinary shares of 0.1p in the Company, representing approximately 0.24% of the Company's issued share capital.

Application has been made to AIM for the admission of the New Ordinary Shares to trading on AIM ("Admission") and Admission is expected to occur on 22 July 2020. The New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares in issue.

Following Admission, the total number of ordinary shares in the Company with voting rights in issue will be 419,056,796. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Trevor Jones
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	e-therapeutics plc
b)	LEI	21380049RHSSJXWKYT18
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 0.1 pence ISIN: GB00B2823H99
b)	Nature of the transaction	Purchase of shares
c)	Price(s) and volume(s)	32,185 ordinary shares at a price of 17.09 pence per share
d)	Aggregated information - Aggregated volume - Price	32,185 ordinary shares 17.09 pence per share Aggregated value: £5,500.52
e)	Date of the transaction	14 July 2020
f)	Place of the transaction	Outside a trading venue

For further information, please contact:

e-therapeutics plc Ali Mortazavi, Executive Chairman Laura Roca-Alonso, Chief Business Officer	Tel: [phone] www.etherapeutics.co.uk
Numis Securities Limited Freddie Barnfield/Duncan Monteith (Nominated Adviser) James Black (Corporate Broking)	Tel: [phone] www.numis.com
FTI Consulting Simon Conway/Stephanie Cuthbert	Tel: [phone] Email:  [e-mail]

About e-therapeutics plc

e-therapeutics plc is an Oxford, UK-based company with a powerful computer-based approach to drug discovery, founded on its industry-leading expertise in network biology to fully capture disease complexity. The Company combines network science, machine learning, artificial intelligence, statistics and access to big data with expertise in drug discovery and development to transform the search for new medicines and intervention strategies.

e-therapeutics has developed an in silico laboratory that enables the rapid screening of millions of compounds and the identification of small sub-sets that are enriched for highly active hits. Its proprietary platform also has novel applications in functional genomics, being able to analyse complex genetic datasets, provide a deep understanding of pathological mechanisms and distil actionable insights for the discovery of novel drugs, biomarkers and diagnostics.

e-therapeutics has deployed and validated its disease-agnostic drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.

 

END

 

 

DSHFFFFIDTISLII